Institute for Ageing and Health, Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, UK.
Neurobiol Dis. 2012 Aug;47(2):155-62. doi: 10.1016/j.nbd.2012.03.033. Epub 2012 Apr 5.
Neurogenesis occurs in the subventricular zone and the sub-granular layer of the hippocampus and is thought to take place in 5 stages, including proliferation, differentiation, migration, targeting, and integration phases, respectively. In Alzheimer's disease (AD) both increased and decreased neurogenesis has been reported and cholinergic activity is assumed to be involved in neurogenesis. The aim of this study was to systematically assess different phases of neurogenesis and their relation to AD and cholinergic pathology. We investigated post-mortem brain tissue from 20 AD patients and 21 non-demented controls that was neuropathologically characterized according to standardized criteria. Hippocampal sections were stained with antibodies against neurogenic markers Musashi-1, nestin, PSA-NCAM, doublecortin, and β-III-tubulin as well as ChAT (choline-acetyltransferase). Using image analysis immunoreactivity was assessed in the subventricular zone, the sub-granular layer, and the granule cell layer by determining the integrated optical density. In the sub-granular layer and the granule cell layer Musashi-1 and ChAT immunoreactivities were significantly lower in AD and decreased with increasing Braak stages. Conversely, immunorreactivities of both nestin and PSA-NCAM were significantly higher in AD and increased with increasing Braak stages while no changes were seen for doublecortin and β-III-tubulin, except for significantly higher doublecortin levels in the granule cell layer of AD cases. Of note, Musashi-1 immunoreactivity significantly correlated with ChAT immuonoreactivity across different Braak stages. In the subventricular zone only nestin immunoreactivity was significantly higher in AD and significantly increased with increasing Braak stages, while no significant differences were seen for all other markers. Our finding of a reduction of ChAT and Musashi-1 levels in AD is compatible with the assumption that cholinergic pathology per se has a detrimental influence on neurogenesis. We conclude that neurogenic abnormalities in AD differ between phases and areas of neurogenesis and stages of AD; while hippocampal stem cells (Musashi-1) decrease, proliferation (nestin) increases and differentiation/migration phase as well as axonal/dendritic targeting (doublecortin and β-III-tubulin) remains virtually unchanged. This suggests an attenuation of stem cells together with compensatory increased proliferation that, however, does not result in an increased number of migratory neuroblasts and differentiated neurons in AD.
神经发生发生于侧脑室下区和海马的颗粒下层,被认为分为 5 个阶段,分别是增殖、分化、迁移、靶向和整合。在阿尔茨海默病(AD)中,既有神经发生增加的报道,也有神经发生减少的报道,并且认为胆碱能活性参与了神经发生。本研究的目的是系统评估神经发生的不同阶段及其与 AD 和胆碱能病理学的关系。我们研究了 20 名 AD 患者和 21 名非痴呆对照者的死后脑组织,这些患者的脑组织根据标准化标准进行了神经病理学特征描述。用针对神经发生标志物 Musashi-1、巢蛋白、PSA-NCAM、双皮质素和 β-III-微管蛋白以及 ChAT(胆碱乙酰转移酶)的抗体对海马切片进行染色。通过确定积分光密度,在侧脑室下区、颗粒下区和颗粒细胞层中使用图像分析评估免疫反应性。在颗粒下区和颗粒细胞层中,AD 患者的 Musashi-1 和 ChAT 免疫反应性显著降低,且随着 Braak 分期的增加而降低。相反,AD 患者的巢蛋白和 PSA-NCAM 免疫反应性显著升高,且随着 Braak 分期的增加而升高,而双皮质素和 β-III-微管蛋白则没有变化,除了 AD 病例的颗粒细胞层中双皮质素水平显著升高。值得注意的是,Musashi-1 免疫反应性与不同 Braak 分期的 ChAT 免疫反应性显著相关。在侧脑室下区,只有巢蛋白免疫反应性在 AD 中显著升高,且随着 Braak 分期的增加而显著增加,而其他标志物则没有显著差异。我们发现 AD 中 ChAT 和 Musashi-1 水平降低与胆碱能病理学本身对神经发生有不利影响的假设一致。我们得出结论,AD 中的神经发生异常在神经发生的不同阶段和 AD 的不同阶段之间存在差异;海马干细胞(Musashi-1)减少,增殖(巢蛋白)增加,分化/迁移阶段以及轴突/树突靶向(双皮质素和 β-III-微管蛋白)基本不变。这表明干细胞衰减伴随着代偿性增殖增加,但这并不会导致 AD 中迁移性神经前体细胞和分化神经元数量增加。